Antithrombotic Activities of a Novel Yoghurt Drink: a Postprandial Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-14

Study Completion Date

2021-08-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The project aims to investigate the antithrombotic activity of the novel yoghurt drink enriched with polar lipids derived from ovine milk. The health claims the formulated novel or functional food on EFSA guidelines "The scientific requirements for health claims related to antioxidants, oxidative damage and cardiovascular health" and in a particular paragraph 5.4, "Claims on reduced platelet aggregation" "Platelet hyperactivity and hypercoagulability states are more commonly observed in subjects with cardiovascular (CV) risk factors. Healthy subjects or participants at very low risk of CV disease normally have non-activated circulating platelets. Reducing platelet aggregation in subjects with platelet activation during sustained exposure to the food/constituent (e.g., four weeks) would be a beneficial physiological effect".

Within this investigation, the postprandial effects of this novel yoghurt drink against platelet aggregation are going to be studied ex vivo in blood from healthy human subjects as described in previously established procedures.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Antithrombotic Activities of a Novel Yogurt Drink

NCT05318911

Cardiovascular Diseases

COMPLETED NA

Acute Assessment of Platelet Reactivity After the Intake of Oleocanthal

NCT03528603

Platelet Aggregation Nutritional and Metabolic Disease Cardiovascular Diseases

COMPLETED NA

Cranberry Juice and Cardiovascular Disease

NCT01295684

Cardiovascular Disease

COMPLETED NA

Acute Effects of Tart Cherry on Uric Acid and Biomarkers of CVD Risk in Healthy Individuals

NCT04960527

Uric Acid Cardiovascular Diseases Gout

COMPLETED NA

Effects of a Beverage Rich in Fruit Extracts on Risk Factors Associated With Cardiovascular Disease

NCT00795834

Cardiovascular Disease

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A: Yoghurt drink (polar lipid) intervention

Group Type EXPERIMENTAL

Novel yoghurt drink containing Polar Lipids

Intervention Type DIETARY_SUPPLEMENT

Postprandial decreased platelet activation/aggregation in subjects, after the yoghurt drink consumption

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Novel yoghurt drink containing Polar Lipids

Postprandial decreased platelet activation/aggregation in subjects, after the yoghurt drink consumption

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Healthy subjects need to have their dietary and dairy intake within the range \[1-2 serves per week\]

Exclusion Criteria

* Subjects will be excluded from the study if they are

* Under medication and intake of dietary supplements
* Treatment for blood clotting disorders or dyslipidaemia

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes